IRB #
STUDY00023435
Title
DELFI-L101 Study: DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study
Principal Investigator
Nima Nabavizadeh
Study Purpose
The purpose of the study is to determine if a blood-based test can be used to identify cancers that may or may not also be seen on images of lungs. The study aims to see if a blood-based test can identify other types of cancers and health conditions.
Medical Condition(s)
Lung Cancer, Esophageal Cancer, Colon Cancer, Rectal Cancer, Pancreatic Cancer, Stomach Cancer, Head and Neck Cancer, Bladder Cancer, Kidney Cancer, Liver Cancer.
Eligibility Criteria
1. Ability to understand and provide written informed consent.
2. Age greater than or equal to 50 years.
3. Greater than or equal to 20 pack-years (pack years = number of packs per day times number of years smoked).
AND one of the following:
Lung Cancer Cohort:
a) High Risk Patients with a pathologic diagnosis of lung cancer inclusive of staging.
b) No prior therapy within the year prior to enrollment.
Non-Lung Cancer Cohort:
a) High Risk Patients with a pathologic diagnosis of non-lung cancer inclusive of staging, originating from one of the following tissues: esophagus (upper), colon or rectum, pancreas, stomach (including lower esophagus), head and neck, bladder, kidney, or liver.
b) No prior therapy within the year prior to enrollment.
Control Cohort:
a) Participants without a cancer diagnosis or stable nodule for at least 1 year by chest CT scan.
Age Range
50 - N/A
Healthy Volunteers Needed
Yes
Duration of Participation
12 months from enrollment and an optional 5 year follow-up period.
Minors Included
No
Contact
Email: cedartrials@ohsu.edu.
Phone: (503) 418-8150.
Sponsor
Delfi Diagnostics, Inc.
Recruitment End
08/16/2026
Compensation Provided
Yes
Compensation
One time $50 cash compensation will be provided at the conclusion of the study visit.
Go Back